Nirsevimab implementation in Catalonia, Spain, reduced emergency department visits and hospital admissions for bronchiolitis ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

A single injection of nirsevimab, a long-acting monoclonal antibody developed to prevent respiratory syncytial virus (RSV) ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.

Clesrovimab joins the monoclonal antibody nirsevimab (Beyfortus), as well as the maternal bivalent RSV prefusion F protein ...

Further, the study showed that nirsevimab’s effect was less pronounced in older children (between six and 23 months), ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

Maternal vaccination and, to a lesser extent, nirsevimab appear to significantly reduce RSV-related hospitalizations in infants.

Get Instant Summarized Text (Gist) Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 season was linked to significant reductions in RSV-associated hospitalizations ...